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Abstract 
Background: It is a common practice for physicians to treat dermatologic 
conditions with medications that are not indicated for the specific condition 
being treated. These "off-label" prescriptions are often for drugs that have both 
well accepted the therapeutic value in the medical community and proven 
efficacy on the basis of results of clinical trials. 
Objective: The aim of this study is to determine the main risk factors of most 
unlicensed and off-label medications used in treatment of dermatological 
diseases worldwide and to make a detailed examination of ethical and legal 
trends, patterns, preventive methods, possible solutions and recommendations 
associated with using unlicensed and off-label drugs in dermatology. 
Methods: A systemic review of the relevant available studies on unlicensed 
and off-label medication uses in dermatology worldwide was performed. 
Results: Ten epidemiological studies regarding the use of unlicensed drugs 
and off-label drugs in dermatology worldwide were identified. The selected 
studies were between the year 1994 and 2014.  
Conclusion: Off-label medications seem to be commonly prescribed in clinical 
practice in dermatology and differs between countries, inpatient and outpatient 
settings and age. However, prescribing off-label medications to patients who 
expect to receive an effective treatment will likely lead to foreseeable ethical 
and legal difficulties. Some of the key ethical issues include the impact on the 
patient autonomous decision, informed consent and nature of the relationship 
between dermatologists and drugs companies. Legally, concerns surrounding 
the clinical implications, litigation for professional misconduct and FDA policies 
on off-label uses. A management guideline for off-label drug use is urgently 
needed. 
Keywords: Unlicensed drugs, off-label drugs, dermatology, prescriptions, 
ethics, legal issues and legislation. 
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Chapter 1.0 
Introduction: 
1.1 Background to the Study: 
"Off-label" means the medication is being used in a manner not specified by the 
Food and Drug Administration (FDA) as an approved packaging label. This 
label is a written report that provides detailed instructions regarding the 
approved uses and doses, which are based on the results of clinical studies that 
the drug maker submitted to the FDA, “said Kelli Miller, the Cleveland Clinic 
Men's Health Advisor”. 
“Many people may be surprised to know that the FDA regulates drug approval, 
not drug prescribing, and doctors are free to prescribe a drug for any [reason 
they think is medically appropriate],” says G. Caleb Alexander, MD, MS, a 
medical ethics advocate and assistant professor of medicine at the University of 
Chicago Medical Center. 
Despite the prominence of off-label drug use, experts say few patients are 
aware that they are receiving a drug off-label and doctors are not required to tell 
a patient that a drug is being used off-label. When a doctor writes a prescription 
to treat an ailment, the patient probably assumes that the drug has been 
approved for that use by the Food and Drug Administration (FDA). When a 
doctor prescribes a drug for an unapproved use, it is called an “off-label” 
prescription. The term refers to the fact that all drugs have “labeling” detailed 
written descriptions of their intended use based on studies submitted to the 
FDA. 
Dermatologists, like other physicians, face a dilemma when attempting to use 
only drugs with regulatory body approved indications. Neither industry or 
regulators want to be accused of experimenting on children, pregnant females 
or old people! In pediatrics, only about 20% of all drugs marketed in the US 
have been labeled for use by infants and children (Jaffe, S., 1994). Such an 
exclusion results in widespread off-label use. One study found that in 36% of 
707 admissions, children received one or more courses of an unlicensed or off-
label treatment (Turner S. et al., 1998). In 731 pregnant patients, 23% took 
more than one drug for off-label indications (Rayburn W. F. and Turnbull G. L., 
1995). 
It is a common practice for dermatologists to treat dermatologic conditions with 
medications that are not indicated for the specific condition being treated. 
These "off-label" prescriptions are often for drugs that have both well accepted 
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therapeutic value in the medical community and proven efficacy on the basis of 
results of clinical trials (Sugarman, J.H. et al., 2002). Off-label prescribing isn't 
necessarily bad. It can be beneficial, especially when patients have exhausted 
all other approved options, as may be the case with rare diseases or cancer. 
Topical steroids are an excellent example of a class of drugs that is used in a 
broad range of clinical disorders, frequently without a particular indication other 
than managing general inflammation. 
 
1.2 Problem Statement: 
In this study, it is argued that the therapeutic use of off-label medications should 
not be permitted in the clinical practice. The use of off-label medications in the 
clinical practice without a full disclosure raises many complex ethical and legal 
concerns. Some of the key ethical issues to be highlighted include the impact 
on an autonomous decision of the patient and the arguments for and against 
the informed consent for off-label use. Also, concerns surrounding the clinical 
implications, the challenged position of FDA, and the reasons for FDA policies 
for off-label use. By continuing to prescribe off-label drugs deceptively, 
dermatologists may not only jeopardize the trust of their patients but may also 
be faced with increasing litigation for professional misconduct.   
 
1.3 Purpose of the Study: 
(1) To determine the risk factors for using unlicensed and off‐label medications 
in Dermatology (2) To study the ethical and legal considerations when using 
unlicensed and off‐label medications in Dermatology (3) To compare the results 
of studies performed in different settings worldwide and identify common 
therapeutics  areas to allow for focused intervention because off-label drug use 
can be a measure of the lack of knowledge concerning dermatological 
treatments. 
 
1.4 Research Question: 
How common and what are the ethical and legal issues of using unlicensed and 
off-label drugs in dermatology worldwide? 
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1.5 Significance of the Study: 
To determine the main risk factors of most unlicensed and off-label medications 
used in treatment of dermatological diseases worldwide and to make a detailed 
examination of ethical and legal trends, patterns, preventive methods, possible 
solutions and recommendations associated with using unlicensed and off-label 
drugs in dermatology. 
 
1.6 Institutional Framework: 
Royal College of Surgeons University in Ireland. 
 
Chapter 2.0 
Methodology: 
2.1 Material and methods: 
In March 2015, a comprehensive and highly sensitive electronic literature 
search strategy of the large biomedical databases was conducted including 
Pubmed, Medline, EMBASE, Cochrane Library, CINAHL, Scopus, TRIP 
(Turning Research into Practice), Web of Knowledge (Science & Social 
Science), Justis and Hastings Center with the following search terms: 
unlicensed drugs, off-label drugs, dermatology, prescriptions, ethics, legal 
issues and legislation. A hand search was conducted in abstracts from relevant 
conferences from major dermatological societies. 
The search was limited to (i) Human data; (ii) Articles written in English and (iii) 
Articles published after the first year included on the searching databases. All 
types of epidemiological studies regarding unlicensed and off-label medication 
use in dermatology were included. Reviews and case reports were excluded.  
Two independent reviewers examined the title and abstract of the articles 
obtained in the first search to recognize relevant studies and extracted data. 
Full texts of all studies meeting the inclusion criteria were reviewed, and their 
bibliographic references were checked for additional sources. The articles upon 
whose relevance both reviewers agreed were included  in the analysis. The 
variables assessed were as follows: the type of study, sample size, instruments 
used, statistical analysis and results. 
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2.2 Methodological Limitations: 
Lack of available and reliable data: a lack of data or reliable data will likely 
lead to limit the scope of analysis, the size of sample or it can be a significant 
obstacle to finding a trend and a meaningful relationship. 
Lack of prior research studies on the topic: citing prior research studies 
forms the basis of the literature review and helps lay a foundation for 
understanding the research problem that are investigated. This limitation can 
serve as an important opportunity to describe the need for further researches. 
Measure used to collect the data: sometimes it is the case that, after 
completing my interpretation of the findings, I discover that the way in which I 
had gathered data inhibited my ability to conduct a thorough analysis of the 
results. 
 
2.3 Limitations of the Researcher: 
Access: if a study depends on having access to database, organizations, or 
documents and, for whatever reason, access is denied or otherwise limited, it 
can affect the results of the study and the reasons for this need to be described 
in the study. 
Time limitation: the time available to investigate a research problem is 
constrained by the due date of the research submission. 
Cultural and other types of bias: we all have biases, whether we are 
conscious of them or not. Bias is when a person, place, or thing is viewed or 
shown in a consistently inaccurate way. It is usually negative though one can 
have a positive bias as well. So, if the author detects bias in prior research, 
he/she must be acknowledged and explain what measures were taken to avoid 
perpetuating prejudice. 
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Chapter 3.0 
Results:  
Ten epidemiological studies regarding the use of unlicensed drugs and off-label 
drugs in dermatology was identified and summarized in Table 1. The selected 
studies were between the year 1994 and 2014.  
Of the ten studies, 3 included pediatric patients with dermatologic diseases. Six 
studies were performed in the USA while only four studies occurred in Europe 
countries.  
 
Table 3.1: Studies related to ethically and legally implications of off-label 
drugs in dermatology. 
Auther Year Title 
Torres 1994 The use of FDA-approved medications for 
unlabeled (off-label) uses. The legal and ethical 
implications 
Sugarman 2002 Off-label prescribing in the treatment of 
dermatologic disease 
Picard 2003 Assessment off-label prescribing in Dermatology 
Blondon 2008 Off-label prescribing 
Parikh 2014 Common use of prescription off-label acne 
therapy in children younger than 12 years old 
Kelly 2012 Ethics in pediatric dermatology 
Silva 2014 Off-label prescribing for allergic diseases in 
children 
Cristopher 2012 Ten common questions and their answers about 
off-label drug use 
Danes 2014 Outcomes of off-label drug use in hospitals: a 
multicentric prospective study 
Largent 2009 Going off-label without venturing off-course: 
evidence and ethical off-label prescribing 
 
 
Altogether, these studies promote the concept of Off-label drug use can be 
motivated by several factors. First, a medication may not have been studied 
and approved for a particular population (e.g., pediatric, geriatric, or pregnant 
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patients). Second, a life-threatening or terminal medical condition may motivate 
a health care professional to give any treatment that is logical and available, 
whether approved by the FDA or not. Third, if one medication from a class of 
drugs has FDA approval, physicians commonly use other medications in the 
same category without specific FDA approval for that use for the same 
indication. Besides, if the pathologic or physiologic features of 2 conditions are 
similar, a physician may use a medication approved for 1 of these conditions for 
both (e.g., eczema and psoriasis). 
Picard et al.(2003) assessed off-label prescribing in Dermatology because of 
the official policy of the French National Health Insurance system is to deny 
reimbursement for drugs prescribed for off-label indications. The objectives of 
their study were 1) to quantify the use of off-label prescriptions by physicians 
from a hospital department of dermatology in France; 2) to characterize these 
off-label prescriptions; 3) to assess data from the literature on the 
appropriateness of these off-label prescriptions. They depended on the 
symptom or the disease that was treated and the type of prescription were 
recorded on standard forms for each patient consulting between February 1 and 
April 1, 2001. 
They found eighty-six percent of prescriptions were labeled, 14% were off-
labeled. Inflammatory and hypersensitivity dermatoses were the most frequent 
indications of off-label prescriptions (26 %). Treatments which most frequently 
corresponded to off-label prescriptions were topical corticosteroids and 
methotrexate. Examination of the literature showed that 70% of the off-label 
prescriptions were not based on strong data from evidence-based-medicine. 
Many off-label prescriptions were made by the most graduate physicians. 
Their study showed a considerable number of off-label prescriptions in 
dermatology. These prescriptions were often related to rare diseases that were 
managed by senior dermatologists. These off-label prescriptions were rarely in 
agreement with data from evidence-based-medicine. 
 
Sugarman et al. stated that it is a common practice for physicians to treat 
dermatologic conditions with medications that are not indicated for the specific 
condition being treated. These "off-label" prescriptions are often for drugs that 
have both well accepted the therapeutic value in the medical community and 
proven efficacy on the basis of results of clinical trials. The purpose of his study 
was to quantify the use of off-label prescriptions for a dermatologic disease by a 
representative sample of physicians in the United States. Data from the 1990-
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1997 National Ambulatory Medical Care Survey, performed by the National 
Center for Health Statistics were used to assess medications prescribed at 
office visits for dermatologic disease. They identified the most common 
diagnoses listed at office visits in which the primary and only diagnosis listed 
was dermatologic. For the leading ten dermatologic conditions for which 
medications are indicated, we categorized each primary drug mention by 
indication. He and his colleagues found that the range of off-label prescribing 
varied from 17% to 73%, with a weighted mean (+/- SD) of 32% +/- 18%. The 
conditions most frequently managed with off-label prescriptions were acne 
rosacea (73%) and actinic keratosis (52%), whereas those with the fewest off-
label prescriptions were atopic dermatitis (17%) and psoriasis (16%). The use 
of off-label prescriptions by dermatologists in the diseases studied ranged from 
7% to 73% with a weighted mean (+/- SD) of 24% (+/- 24%), whereas the range 
for non-dermatologists was 18% to 96% with a weighted mean (+/- SD) of 34% 
(+/- 18%). 
They concluded that Off-label prescribing was common in the management of 
dermatologic conditions. Also,  it is currently within the standard of care to use 
off-label prescriptions in the treatment of dermatologic disease. 
 
In a study by Danes et al., a multi-centric prospective cohort study was carried 
out on 226 patients in five tertiary hospitals from May 2011 to May 2012. 
Information on clinical characteristics of patients, drugs, outcomes and costs 
was collected. Patients were followed up for 6 months, and information was 
assessed by reviewing clinical records and interviewing physicians. The study 
aimed to assess the clinical evidence, outcome and cost of off-label use of 
medicines in the hospital setting. 
The median (interquartile range (IQR)) age of patients was 46 (33-62) years; 59 
% were women. Patients had received a median of three previous treatments, 
and a lack of response (or suboptimal) was the primary reason for off-label use 
(72.1 %). A total of 232 off-label medicines were administered for 102 different 
indications. The most frequent medicines were rituximab (49; 21.1 %), 
botulinum toxin (25; 10.7 %) and omalizumab (14; 6.0 %). In 117 (51.8 %) 
cases, the level of clinical evidence for their use was low. A partial clinical 
response was observed in 82 patients (36.3 %), complete response in 71 (31.4 
%) and stabilization in 11 (4.9 %). A total of 58 (26.5 %) patients had adverse 
effects, which in 11 (4.9 %) were severe. The median (IQR) cost per patient 
was 2,943.07 Euro (541.9-5,872.54). 
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The authors concluded that there was a high variability of off-label medicines 
and indications. Although the clinical evidence of off-label medicines was often 
low, clinical response was observed in many patients with previous multiple 
treatment failures, but at the expense of some adverse effects and a high cost. 
Registers of patients would be helpful for clinical decisions although clinical 
trials are needed. 
 
Blondon et al. (2008) explored that off-label prescribing and unlicensed drug 
use are common in all fields of medicine and may be encountered in 
therapeutic guidelines. The term does not imply improper nor illegal use, and 
may provide the only available treatment for "orphan" conditions, or for certain 
populations (children, pregnant women, very old patients). Off-label drug use 
should be based on sound scientific evidence of efficacy and safety. In 
Switzerland, patients need to be informed that health insurance coverage is not 
guaranteed with off-label use. The prescribing physician bears the responsibility 
of off-label use with the possibility of unanticipated risks, and should, therefore 
be prepared for possible malpractice suits. 
 
Largent et al. (2009) commented on several previous articles have addressed 
the appropriateness of off-label prescribing and the attendant ethical and 
professional obligations. Though useful, these accounts have distinctive 
limitations. They treat the phenomenon of off-label prescribing as monolithic 
and require rigorous informed consent for all situations; they address issues 
related to off-label prescribing at a particular institutional level, such as the 
hospital formulary, limiting their applicability to diverse practice environments; or 
they address off-label prescribing at a regulatory level, which does not attend to 
immediate ethical concerns. Practicing physicians need a comprehensive and 
workable ethical framework that prioritizes scrutiny of off-label prescribing and 
links the certainty of net benefit to physician responsibilities. These issues have 
gained even greater importance following the recent issuance by the FDA of 
revised “Good Reprint Practices.” 
This formal guidance permits pharmaceutical companies to encourage off-label 
use by distributing peer reviewed articles relating to off-label use of their drugs. 
Besides, a November 2008 rules change made Medicare coverage automatic 
for a wider array of off-label uses of cancer drugs. New medications reaching 
the market, aggressive marketing of off-label uses to patients as well as to 
physicians, patient expectations that doctors will do “something,” and concerns 
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regarding rising health care costs underscore the importance of practical 
guidance for physicians. 
They concluded that off-label use is an important area of practice in which 
evidence gaps should trigger more reflection and scrutiny. Four characteristics 
of off-label use signal to physicians the need for a higher level of control: new 
drugs, novel off-label uses, drugs with known serious adverse effects, and high-
cost drugs. By classifying off-label uses as supported, suppositional, or 
investigational, this conceptual framework grounds recommendations for 
prescribing practices in a judgment of the strength of the evidence for net health 
benefit. This elevates the role of evidence in the otherwise unregulated realm of 
off-label prescribing and will help physicians in exercising their responsibility for 
applying evidence in practice in a rigorous fashion. 
 
Torres (1994) stated that physicians increasingly use Food and Drug 
Administration (FDA)-approved drugs (medication) for unlabeled (off-label) 
indications. The ethical and legal implications of these actions are not always 
clear.  
One prescribes a drug in the hope that medication will benefit the person to 
whom it is given. Every drug has the potential to cause effects on the body that 
can be beneficial or adverse. Adverse reactions can range in seriousness from 
relatively mild to fatal.1 One estimate showed that adverse drug reactions 
handle 1.0% to 3.5% of admissions to medical wards. One government 
estimate showed that 130 000 US hospital-based deaths per year were caused 
by adverse drug reactions. These adverse reactions can occur with proper use 
(idiosyncratic) or because of improper drug use. As a result, no drug can be 
considered absolutely safe. 
In his article, he examined the common law and federal statutory regulations 
concerning this issue and also explore some of the ethical and financial matters 
involved. 
 
To assure safety to US consumers, Congress established the Federal Food, 
Drug and Cosmetic Act (FDCA), requiring new drug products to demonstrate 
safety and effectiveness for their indications. The FDA administers the FDCA 
and must determine whether a drug is safe and efficient. The FDA regulations 
as they relate to the FDCA have led to requirements for relatively long and 
exhaustive animal and human testing with difficult testing procedures. This 
process keeps most dangerous and useless drugs off the market but results in 
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approximately 4000 drugs being rejected for every one that makes it. In 
practical terms, the cost of discovering and developing a new drug in the USA 
can exceed $75 million, and the time required to advance a drug from an 
investigational status to approval by the FDA could consume up to 10 years. 
This in turn, has resulted in some US physicians using FDA-approved 
purposes. “Whatever the initial cause, prescriptions are written for unlabeled 
purposes because of discussions by doctors and reports in the medical 
literature and thus some unlabeled uses become widespread before the new 
uses are approved by the FDA. This use of FDA-approved drugs for unlabeled 
(off-label) purposes raises many legal and ethical questions. Physicians need to 
be knowledgeable in this area.  
 
On the other hand, Diana Silva, Ignacio Ansotegui and Mário Morais-Almeida 
(2014) discussed Off-label prescribing for allergic diseases in children. They 
recognized that a high percentage of prescriptions performed for allergy 
treatment in daily clinical practice were off label. The clinicians struggle on a 
daily basis with the responsibility to balance risk-benefits of an off-label 
prescription while involving the patients and their families in this decision. It is 
crucial to increasing awareness of this reality not only for the clinician but also 
to the global organizations and competent authorities. New measures for 
surveillance of off-label use should be established, namely through population 
databases implementation. There is a need for new proposal to correct the 
inconsistency between the priorities for pediatric drug research, frequently 
dependent on commercial motivations, in order to comply with the true needs of 
the children, especially on the respiratory and allergy fields. 
The majority of drugs prescribed have not been tested for children and safety 
and efficacy of children’s medicines are frequently supported by the low quality 
of evidence. In Europe, the percentage of authorized medicines for children is 
33.3%. This is explained by the lack of clinical research in this population, 
caused by ethical, scientific and technical issues, but also commercial priorities. 
Therefore, most of the therapies prescribed to children are on an off-label or 
unlicensed basis. 
Global legislation and regulatory efforts have been done to overpass these 
limitations aiming to produce proper research in the pediatric population, 
promoted by an International Conference on Harmonization (ICH) guidelines for 
clinical investigation of medicinal products in the pediatric population. Since 
1997, the Food and Drug Administration (FDA) in the United States of America 
(US) produced several regulation/legislation initiatives (Pediatric Rule 
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Regulation, 1998; Best Pharmaceutical for Children Act, 2002 and Pediatric 
Research Equity Act, 2003). In Europe (EU), followed by US experiences, new 
regulations were implemented since January 2007. In both continents the 
measures were taken enclosed financial incentives to the industry, the addition 
of 6 months extra patent protection and an additional two years market 
exclusivity for orphan medicines. Furthermore, World Health Organization 
(WHO) adopted in 2007 the WHA60.20 Resolution “Better Medicines for 
Children” to undertake activities in the interest of improving pediatric medicines 
research, regulation and rational. One of the most important was the 
establishment of the Model List of Essential Medicines for Children, now in its 
4th version. However, major discrepancies between drug prescription patterns 
in children and the drugs granted pediatric exclusivity still exists. Looking back 
to the last 5 years of the Pediatric Regulation from the European Medical 
Agency (EMA) [Regulation(EC) N°1901/2006], 600 pediatric investigation plans 
(PIP) were performed, of those 453 referred to not yet authorized drugs, while 
the remaining related to new indications. However, no specific therapeutic area 
was addressed more than the other, and as far as Pneumology and Allergology 
are considered, they only accounted for 4% of PIP. At the same time, 30% of 
the prescribed drugs for children are for the respiratory system. This suggests 
that pediatric studies still do not address the real need in pediatric drug 
development despite an overall increase of medicines now available for 
children. Most of the drugs available on the market, especially those considered 
for the treatment of allergic diseases, are still not specifically tested in children, 
particularly in the younger ones. 
In a joint initiative, the European Academy of Allergology and Clinical 
Immunology (EAACI), the EU-funded network of excellence, the Global Allergy 
and Asthma European Network (GA2LEN), the European Dermatology Forum 
(EDF) and the World Allergy Organization (WAO) published a guideline for 
urticaria management. In it was recommended as the first line treatment for 
urticaria the use of oral antihistamines in an up-dosing step up therapy until up 
to 4 times the dose. These new recommendations were also advised for 
children, adjusting the dose accordingly to the weight. Recent randomized, 
double-blind, placebo-controlled trials in adults support the efficacy and safety 
of this up-dosing use, namely in cold contact urticaria. Nevertheless, due to the 
absence of controlled trials in children, these changes were not updated in the 
SPC of the anti-histamines in the market and as stated above only a few of 
them were actually studied for their long term effects in children. This explains 
why a large portion of the off-label type of use when considering anti-histamines 
is due to a different dose prescription. For chronic disease, it is also important 
not only efficacy and safety but also compliance with the treatment. Children 
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pediatric formulations, namely under six years of age, are usually liquid and it is 
necessary to make them stable, sterile, pleasant and long lasting. Furthermore, 
as children grow, drug doses should be adapted to weight and, to avoid dosing 
errors, the means to deliver accurate doses of these liquid formulations need to 
be available. In atopic dermatitis, antihistamines also are considered as a 
potential benefit to reducing pruritus, and although no evidence exists to 
support their role in the treatment they can be useful in reducing this disturbing 
symptom in children. 
Accordingly to the most recently published guidelines for atopic dermatitis the 
main treatment is skin hydration, topical anti-inflammatory medications and 
antipruritic therapy. For anti-inflammatory medication, topical corticosteroids or 
topical calcineurin inhibitors are used. For topical corticosteroids, numerous 
substances are available, grouped by potency. Potent and very potent 
corticosteroids (Group III and IV) are more likely to cause systemic or local side 
effects (like adrenal suppression, skin atrophy or striae) than group I (mild) and 
II (moderate strength); therefore the first should be avoided for treatment in 
infants, whose higher surface area to body weight ratio and age-dependent 
maturation of the skin barrier function leaves them vulnerable to overdosing. 
According to the FDA, use of these products is also limited by age and duration 
of treatment. Still and especially from birth to 4 years old, topical corticosteroids 
were prescribed off-label in 13% of all prescriptions, of those 58% due to high 
dosage use. Recent guidelines recommend that for mild disease activity, a 
small amount of topical corticosteroids twice to thrice weekly until reaching a 
mean monthly dose of 15 grams in infants, 30 g in children and up to 60 to 90 g 
in adolescents and adults. 
Nowadays new topical anti-inflammatory alternatives include calcineurin 
inhibitors and fourth generation corticosteroids. These fourth generation 
corticosteroids, like methylprednisolone aceponate, seem to have a favorable 
benefit-risk-ratio in this age group. Regarding topical immunomodulators, 
calcineurin inhibitors, like tacrolimus and pimecrolimus, as they don’t cause skin 
atrophy, are favored for long-term management and to be used in delicate body 
areas, such as the eyelid region, the perioral skin, genital area, the axilla or the 
inguinal fold. As a result of the immunosuppressant activity of these drugs, 
there are concerns about their potential to promote skin infections and 
malignancies, particularly lymphomas, following long-term treatment. These 
drugs are only approved for children with more than two years of age by FDA 
and EMA. Due to the high prevalence of atopic dermatitis in children, which 
begins in over 60% of cases during the first year of life, usually affects more 
sensitive skin areas and have a higher body surface/volume ratio that enhances 
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the risk of systemic exposure to corticosteroids, it was seen an increase of use 
of topical calcineurin inhibitors. Off-label use, particularly in infants in the US, 
reached a high prevalence of prescriptions in 2004, approximately 525,000 
(14% of yearly prescriptions) for pimecrolimus and 69,000 (7%) for tacrolimus. 
This led FDA to include a black box warning in 2005, changed to a box warning 
in 2006, on the labels of topical tacrolimus and pimecrolimus. Still, a further 
discussion has occurred and even with large epidemiological data, at the 
current time, FDA maintains that may be “a possibility of an association”. 
However, guidelines recommend clinicians to use tacrolimus ointment, 
especially for eczema on the face, eyelid, and skin folds that are unresponsive 
to low-potency topical steroids in children older than two years. Other systemic 
drugs for atopic dermatitis treatment also recommended off-label in children 
and adolescents is cyclosporine, however only reserved for the most severe 
and refractory to classical treatment and usually demanding specialized care. 
While Parikh and his colleagues (2014) wrote about the common use of 
prescription off-label acne therapy in children younger than 12 years old in the 
USA. Acne is occurring more frequently in younger age groups, but most 
available treatments are considered off-label in small children. As the 
epidemiology of acne has changed to include younger children over the past 20 
years, neither regulators, pharmaceutical companies, nor clinicians have 
understood the need or value of obtaining regulatory sanctions for problems 
physicians have managed using clinical judgment. The objective of the study 
was to analyze the frequency of off-label acne treatment according to age and 
other demographic factors. They searched the National Ambulatory Medical 
Care Survey from 1993 to 2010 for visits in children younger than 12 years of 
age for the diagnosis of International Classification of Diseases, Ninth Revision, 
code 706.1. They tabulated leading acne treatments and assessed factors 
associated with off-label prescribing. Off-label but appropriate acne treatments 
were used in 29% of acne visits for children younger than 12 years of age. 
Dermatologists were more likely than pediatricians to prescribe off-label 
treatment (p < 0.001). The most frequently used off-label treatments were 
topical retinoids, followed by oral antibiotics. There was no significant trend in 
the rate of off-label prescribing over time (p = 0.40). Off-label treatment is well 
within the standard of care for young children with acne. More data on the use 
of topical retinoids in small children will improve our understanding of their use, 
which may help optimize treatment outcomes for children with acne. 
 
Kelly and his colleagues (2012) wrote about ethics in pediatric dermatology and 
raised the concept of the patient-parent-physician relationship is central to 
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studying medical ethics in pediatric dermatology. The rights of children in 
medical decision making are ambiguous, and parents and physicians will often 
override the autonomy of a child when a particular treatment is deemed to be in 
the child's best interest. The use of physical restraint to enforce a treatment 
should be justified, and a reasonable attempt should be made to ensure the 
cooperation of the child, if possible. Medical photography is central to the 
practice of pediatric dermatology in that it allows for serial observation of 
cutaneous lesions over time. Established guidelines and standards should be 
followed. They identified that pediatric Dermatologists frequently prescribe 
medications off-label; if following established professional standards, and 
prescribing with real intention, off-label prescribing can be appropriate and 
rational. 
 
Christopher W., Christopher B. and William L. (2012) from Mayo Clinic, USA 
tried to answer the common ten questions about off-label drug use.  Their 
article introduced and answered ten questions regarding off-label drug use 
(OLDU) in an effort to clarify the practice's meaning, a breadth of application, 
acceptance, and liabilities.  OLDU is a polarizing term because it can be 
associated with great benefit or harm to patients. In addition, OLDU, along with 
allegations of pharmaceutical company promotion of OLDU, has been the 
cause of major lawsuits and historically large out-of-court legal settlements. 
Therefore, all health care professionals have likely heard the term OLDU used, 
yet they propose that many have an under-appreciation of its definition, 
prevalence, and implications. 
 
Chapter 4.0 
Discussion: 
The term off-label drug use (OLDU) is used extensively in the medical literature, 
continuing medical education exercises, and the media but many health care 
professionals have an under-appreciation of its definition, prevalence, and 
implications. This article introduces and determines the main risk factors of 
most unlicensed and off-label medications used in treatment of dermatological 
diseases worldwide and to make a detailed examination of ethical and legal 
trends, patterns, preventive methods, possible solutions and recommendations 
associated with using unlicensed and off-label drugs in dermatology.  
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Off-label drug use involves prescribing medications for indications, or using a 
dosage or dosage form, which have not been approved by the US Food and 
Drug Administration. Since the Food and Drug Administration does not regulate 
the practice of medicine, OLDU has become common. It occurs in every 
specialty of medicine, but it may be more common in areas of medicine in which 
the patient population is less likely to be included in clinical trials (e.g., pediatric, 
pregnant, or psychiatric patients) or for external use like in dermatology. 
Pharmaceutical companies are not allowed to promote their medications for an 
off-label use, which has led to several large settlements for illegal marketing. To 
limit liability, physicians should prescribe medications only for indications that 
they believe are in the best interest of the patient. Besides, health care 
professionals should educate themselves about OLDU to weigh the risks and 
benefits and provide the best possible care for their patients. 
 
Chapter 5.0 
The Stages of Drug Development, Review and Prescribing 
5.1 The Stages of Drug Development and Review: 
The path a drug travels from a lab to a medicine cabinet is usually long and 
every drug takes a unique route, this explains why a limited number of 
medications are approved on-label by FDA. 
Common problems include unexpected safety issues that crop up or failure to 
demonstrate a drug's effectiveness. A sponsor may need to conduct additional 
studies--perhaps studies of more people, different types of persons, or for a 
longer period of time. Manufacturing issues are also among the reasons that 
approval may be delayed or denied. Drugs must be manufactured in 
accordance with standards called good manufacturing practices, and the FDA 
inspects manufacturing facilities before a drug can be approved. If a facility is 
not ready for inspection, approval can be delayed. Any manufacturing 
deficiencies found a need to be corrected before approval.  
Investigational New Drug Application (IND)--The pharmaceutical industry 
sometimes seeks advice from the FDA prior to submission of an IND. 
1- Animal tested 
Sponsors--companies, research institutions, and other organizations that take 
responsibility for developing a drug. They must show the FDA results of 
preclinical testing in laboratory animals and what they propose to do for human 
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trials. At this stage, the FDA decides whether it is reasonably safe for the 
company to move forward with testing the drug in humans. 
2- IND Application 
Clinical Trials--Drug studies in humans can begin only after an IND is reviewed 
by the FDA and a local institutional review board (IRB). The board is a panel of 
scientists and non-scientists in hospitals and research institutions that oversee 
clinical research.  
IRBs approve the clinical trial protocols, which describe the type of people who 
may participate in the clinical trial, the schedule of tests and procedures, the 
medications and dosages to be studied, the length of the study, the study's 
objectives and other details. IRBs make sure the study is acceptable, that 
participants have given consent and are fully informed of their risks and that 
researchers take appropriate steps to protect patients from harm. 
3- Phase 1 Clinical Trial 
Phase 1 studies are usually conducted in healthy volunteers. The goal here is 
to determine what the drug's most frequent side effects are and, often, how the 
drug is metabolized and excreted. The number of subjects typically ranges from 
20 to 80. 
4- Phase 2 Clinical Trial 
Phase 2 studies begin if Phase 1 studies do not reveal unacceptable toxicity. 
While the emphasis in Phase 1 is on safety, the emphasis in Phase 2 is on 
effectiveness. This phase aims to obtain preliminary data on whether the drug 
works in people who have a certain disease or condition. For controlled trials, 
patients receiving the drug are compared with similar patients receiving a 
different treatment--usually an inactive substance (placebo), or a different drug. 
Safety continues to be evaluated, and short-term side effects are studied. 
Typically, the number of subjects in Phase 2 studies ranges from a few dozen 
to about 300. 
5- Phase 3 Clinical Trial 
At the end of Phase 2, the FDA and sponsors try to come to an agreement on 
how large-scale studies in Phase 3 should be done. How often the FDA meets 
with a sponsor varies, but this is one of two most common meeting points prior 
to submission of a new drug application. The other most common time is pre-
NDA--right before a new drug application is submitted.   
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Phase 3 studies begin if evidence of effectiveness is shown in Phase 2. These 
studies gather more information about safety and efficacy, studying different 
populations and different dosages and using the drug in combination with other 
drugs. The number of subjects usually ranges from several hundred to about 
3,000 people. 
6- Review Meeting 
Post-market requirement and commitment studies are required of or agreed to 
by a sponsor, and are conducted after the FDA has approved a product for 
marketing. The FDA uses post-market requirement and commitment studies to 
gather additional information about a product's safety, efficacy, or optimal use. 
7- NDA Application 
New Drug Application (NDA)--This is the formal step a drug sponsor takes to 
ask that the FDA consider approving a new drug for marketing in the United 
States. An NDA includes all animal and human data and analyzes of the data, 
as well as information about how the drug behaves in the body and how it is 
manufactured. 
8- Application Reviewed  
When an NDA comes in, the FDA has 60 days to decide whether to file it so 
that it can be reviewed. The FDA can refuse to file an application that is 
incomplete. For example, some required studies may be missing. In 
accordance with the Prescription Drug User Fee Act (PDUFA), the FDA's 
Center for Drug Evaluation and Research (CDER) expects to review and act on 
at least 90 percent of NDAs for standard drugs no later than 10 months after the 
applications are received. The review goal is six months for priority drugs. 
 
5.2 Drug Prescription: 
5.2.1 Who are allowed to write a medical prescription (on-label or even off-
label drug)? To answer this question, read the following: 
A prescriber is a healthcare professional who can write a prescription. This 
applies to both hospital prescriptions and private prescriptions. 
Appropriate practitioners can be: independent prescribers and supplementary 
prescribers. 
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5.2.2 Independent Prescribers 
Independent Prescribers are healthcare professionals who are responsible for: 
assessing patient’s health and making clinical decisions about how to manage 
the condition, including prescribing medication. 
They include: doctors, such as GP or a hospital physician, dentists, who may 
prescribe medication to treat a condition affecting your teeth,  nurse, pharmacist 
(independent prescriber, who can prescribe any medicine for any medical 
condition within their competence, including some controlled medicines (except 
diamorphine, cocaine and dipipanone for the treatment of addiction)) and 
optometrist (independent prescriber, who can prescribe any medicine for 
conditions that affect the eye and surrounding tissue, but cannot prescribe any 
controlled medicines independently). 
 
5.2.3 Supplementary prescribers 
Supplementary prescribers are responsible for continuing health care after an 
independent prescriber has assessed a patient’s health. They work with the 
independent prescriber to fulfill a clinical management plan agreed between the 
prescribers and the patient. 
Supplementary prescribers include: nurses/midwives, pharmacists, podiatrists 
(foot care specialists), physiotherapists (healthcare professionals who use 
physical techniques, such as massage and manipulation, to promote healing), 
diagnostic and therapeutic radiographers (specialists in using medical imaging 
techniques, such as X-rays), optometrists (healthcare professionals who 
examine eyes, test sight, prescribe and dispense glasses and contact lenses)  
A supplementary prescriber can prescribe any medicine, including controlled 
medicines, for any condition within their competence under the agreed clinical 
management plan. For example, GP (an independent prescriber) may assess a 
condition such as chronic obstructive pulmonary disease (COPD) and refer you 
to a specialist physiotherapist (a supplementary prescriber) to manage your 
long-term care. The physiotherapist will be able to prescribe medicines, such as 
inhalers, under a clinical management plan. 
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Chapter 6.0 
Some examples of using off-label drug in Dermatology: 
Off-label medications seem to be commonly prescribed in clinical practice in 
dermatology and differs between countries, inpatient and outpatient settings 
and age. To know how using off-label drug is very common in dermatology, 
these are some examples: 
In view of their unique mechanism of action, topical retinoids are prescribed 
widely in dermatology for both indicated purposes and several worthwhile, 
evidence-based off-label uses. For seasoned clinicians, prescribing medications 
off-label can be efficacious and even practical.  A recent study evaluating off-
label prescribing in treating dermatologic disease concluded that it is currently 
within the standard of care to use off-label prescriptions in treating dermatologic 
disease (Sugarman, Fleischer, & Feldman, 2002). However, practitioners who 
prescribe, dispense, or administer medications for an off-label use should have 
a full understanding of the rationale for such use, as well as any potential legal 
liabilities (Keltz, 2003)   
Clinicians should consider using a topical retinoid for first-line management for 
acne treatment (Wolf, 2002). It reverses thickening of the stratum corneum and 
the abnormal desquamation of keratinocytes (Verschoore et al., 1993). Acne 
therapy with retinoids can be frustrating in the beginning. An exacerbation of 
acne often occurs in the first 2 to 4 weeks of therapy as the follicular epithelium 
is loosening. Fortunately, by the end of the 2nd month, a significant 
improvement with the acne (Prystowsky, 2001) and remission of irritation is 
typically noted. To enhance compliance, the patient should be aware of these 
expected sequelae. 
Topical retinoids are often used off-label for treating actinic keratosis (AKs/pre-
cancers) and actinic lentigines (freckles) in view of the ability to decrease 
melanogenesis, its antiproliferative effect, antipromoter effect, and 
prodifferentiation effect (Goldfarb, 2000). Although the actual number of solar 
lentigines may not change with adapalene, improvement of discrete 
pigmentation and significant color reduction occurs (Goldfarb, 2000). Topical 
tretinoin decreases the number of AKs on the face by approximately 50% when 
used as monotherapy over a minimum of 6 months (Prystowsky, 2001). Topical 
tretinoin effectively treats photodamage. Human studies have found tretinoin to 
be noncarcinogenic and can prevent the formation of UV-induced lesions 
(Baumann, 2003). Since topical tretinoin's ability to normalize the differentiation 
of dysplastic epithelium in AKs, it can be considered for chemoprevention in 
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patients at high risk of basal or squamous cell carcinomas (Prystowsky, 2001). 
Retinoids provide an alternative for patients with significant photodamage who 
have no objections to off-label usage, who might be at risk for AKs, and who are 
looking for a gentle therapy (Goldfarb, 2000). 
Transplant recipients are a unique subset of people for whom the sequelae of 
sun damage are even more hazardous. Within 5 years of immunosuppression, 
40% of transplant recipients experience premalignant skin tumors such as AKs 
and Bowen's disease, as well as skin cancers such as squamous cell 
carcinoma (SCC) and basal cell carcinomas (Stockfleth, Ulrich, Meyer, & 
Christophers, 2002). Early, preventative treatment could halt the development 
of invasive SCC (Euvrard, 2000). Topical retinoids can provide an often-
favorable alternative to cryotherapy, and other destructive regimens, in persons 
with multiple lesions (Stockfleth et al., 2002). 
Chemopreventative treatment with retinoids has been studied in patients with 
oropharyngeal carcinoma. The mechanism of action of vitamin A modulates 
growth and differentiation of cells, and vitamin A deficiency enhances 
susceptibility to carcinogenesis. Side effects of topical use have been minimal. 
Suppression of oral leukoplakias has been noted with the direct application of 
retinoic acid. Treatment may be justified in those patients with recurrent and 
persistent lesions that may otherwise progress (Gorsky & Epstein, 2002). 
Rosacea is a common, multifactorial, multiphasic, inflammatory skin disease in 
which chronic flushing and blushing results in permanently dilated blood vessels 
(telangiectasias). Although there is no known cure, rosacea can be managed 
and controlled with medication (Bergfeld, 1999). Many first-line treatments have 
been refractory to this condition. In a comparison study regarding the efficacy of 
topical tretinoin and low-dose oral isotretinoin in rosacea, low-dose oral 
isotretinoin and topical tretinoin cream appear to be beneficial in treating severe 
or recalcitrant rosacea (Ertl, Levine, & Klingman, 1994). Systemic medications 
are not without risk. If possible, the risk of systemic side effects should be 
minimized. Recent clinical research suggests that topical tretinoin minimizes the 
manifestations of papular-pustular rosacea within a relatively short treatment 
duration (Bergfeld, 1999). Topical retinoids have often been considered 
controversial as a treatment for rosacea because of the associated increased 
redness, burning, and peeling of the skin. This irritation, however, has been 
typically temporary. According to a recent literature review, in addition to the 
traditional avoidance of triggers along with topical and oral antibiotic therapy, 
current effective treatment now also includes both topical and oral retinoid 
therapy, topical vitamin C therapy, and cosmetic surgery (Cohen & Tiemstra, 
2002). 
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Human papillomavirus (HPV) infections are widespread and cause a plethora of 
benign clinical lesions on the skin and mucous membranes (Fitzpatrick et al., 
1997). Topical retinoic acid has shown moderate, favorable results for treating 
verruca plantaris and verruca plana (Verschoore, 1993). Topical tretinoin is 
often beneficial when treating facial verruca. As dermatology practitioners, we 
have noticed that treatment of facial verruca with tretinoin is less irritative and is 
comparatively efficacious to imiquimod (Aldara). 
Increased epidermal proliferation and new collagen formation contribute to the 
improvement of hypertrophic scars, keloids, and acne scars (Verschoore, 
1993). In an open-label, multicenter, prospective study, topical tretinoin 0.1% 
significantly improved the clinical appearance of pregnancy-induced stretch 
marks (Rangel, Arias, Garcia, & Lopez-Padilla, 2001). Striae originating from 
weight gain or endocrine-related disorders could likewise benefit from the use of 
topical retinoid therapy. 
Lichen planus (LP) is an acute or chronic inflammatory dermatosis involving 
skin and/or mucous membranes. Topical retinoic acid (tretinoin) is an effective 
maintenance therapy for cutaneous lichen planus and can contribute to 
preventing recurrence (Verschoore, 1993). This is most likely due to the 
increased epidermal proliferation and collagen-forming activities of topical 
retinoids. The rationale for using tazarotene in oral lichen planus (OLP) is its 
regulatory action on the growth and differentiation of keratinocytes and on 
inflammation (Petruzzi et al., 2002). Compared to control, topical tazarotene 
showed a significant reduction of lesions and remote transitory side effects 
(burning sensations and taste abnormalities). Topical tazarotene may provide a 
valuable therapeutic tool in treating hyperkeratotic oral lichen planus (Petruzzi 
et al., 2002). 
Melasma is an acquired light or dark brown hyperpigmentation that rapidly 
evolves. It is limited to sun-exposed areas, most often on the face. Genetic 
predisposition, solar UV radiation, hormones, and several drugs have been 
identified as notable factors in the pathogenesis of melasma. Treatment 
consists of sun protection, 4% hydroquinone cream twice daily, with adjunctive 
tretinoin 0.05% to 0.1% cream at bedtime. Sunbathing is contraindicated since 
this can result in the reversal of months of topical therapy. Tretinoin is 
reasonably well tolerated and increases the efficacy of hydroquinone (Pathak, 
Fitzpatrick, & Kraus, 1986). Patients with dermal melasma do not respond well 
to hydroquinone and tretinoin. The best therapy results are obtained in those 
presenting with epidermal or mixed melasma (Pathak et al., 1986). Wood's 
lamp examination is helpful to differentiate melasma involvement in skin 
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phototypes I to IV and accentuates epidermal melasma, not dermal melasma. It 
is of no value in skin phototypes V and VI (McMichael, 2003). 
Darier's disease is a rare, noncurable, genodermatosis affecting approximately 
1 in 55,000 people (English, 2000). This disease is often associated with 
disfiguring, symmetrical, generalized pruritic cutaneous eruptions occurring in 
the seborrheic areas that can be malodorous, often detrimental to the self-
esteem and quality of life of these individuals. Retinoids (oral and topical) are 
effective for treating Darier's disease; however, the mechanism of action is not 
known (English, 2000). Oral retinoids are the most effective treatment but are 
associated with troublesome side effects (Cooper & Burge, 2003). Case studies 
have reported favorable success regarding the use of tazarotene gel and 
adapalene gel for this disorder (English, 2000). 
Pretreatment of skin with all-trans retinoic acid (tretinoin) can enhance wound 
healing. Histological effects of tretinoin demonstrate compaction of the stratum 
corneum, epidermal acanthosis with correction of atypia, an increase in small 
vessels, and increased cellularity in the upper dermis. Tretinoin dramatically 
accelerates wound healing in a photodamaged skin (Popp, Klingman, & 
Stoudemayer, 1995). Pretreatment of skin with topical tretinoin may be 
beneficial in reducing healing times of patients undergoing electroepilation 
(Anthony, Miller, & Dinehart, 1991). Pretreatment with topical all-trans retinoic 
acid (tretinoin) has also reversed impaired wound healing in genetically diabetic 
mice (Kitano, Yoshimura, Uchida, Sato, & Harii, 2001). 
The employment of topical retinoids in wound healing is flourishing. Retinoic 
acid reverses the inhibitory effects of glucocorticoids on wound healing and 
expedites the formation of healthy granulation tissue. Pretreatment with tretinoin 
prior to epidermal injuries such as chemical peeling and dermabrasion 
accelerates wound healing. Short-contact tretinoin therapy is a novel modality 
for treating chronic ulcers and stimulating granulation tissue formation 
(Paquette, Badiavas, & Falanga, 2001). A comparison of tretinoin, adapalene, 
and collagenase in an experimental model of wound healing concluded that 
tretinoin and adapalene contributed to the wound healing process resulting in 
an enhancement of collagen production, angiogenesis, and granulation tissue 
formation (Basak et al., 2002). 
Granular parakeratosis is a rare, acquired dermatosis characterized by keratotic 
papules, located in intertriginous regions. A recent case report demonstrated 
rapid clearance of such lesions to the axilla, with topical administration of 
tretinoin (Brown & Heilman, 2002). 
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This is a condition that consists of a primary extraskeletal bone formation that 
arises within the skin. Local application of tretinoin decreases the number of 
papules over the face in those patients suffering from this condition. Response 
time varies from a few weeks to 6 months. Tretinoin cream can be considered 
in treating multiple miliary osteoma cutis of the face, especially when dealing 
with small and superficial lesions (Cohen, Chetov, Cagnano, Naimer, & Vardy, 
2001). 
Patients with alopecia areata can have patchy or confluent hair loss on the 
scalp and/or body. Treatment options are tailored to the severity of the disease, 
including either irritants/immunogens or local/systemic immunosuppressives 
(Olsen, 2003). Combination therapy is often used. Beneficial treatment 
outcomes, using topical tretinoin for hair growth disorders, have been reported 
(Hass & Arndt, 1986). Safety and efficacy of 0.05% tretinoin and adjunctive 
intralesional triamcinolone were evaluated for treating alopecia areata. Topical 
tretinoin appeared to enhance the hair growth producing effect of the 
intralesional triamcinolone. Tretinoin helps to normalize cell differentiation, and 
the familiar retinoid dermatitis may contribute to the stimulation of hair growth 
by creating an immune response. Topical tretinoin coupled with topical minoxidil 
has also shown promising results in treating alopecia areata. 
Wat H. and Dytoc M. (2014) researched to provide evidence-based clinical 
guidelines for the off-label use of topical vitamin D in the treatment of 
dermatologic disease. Topical vitamin D is approved by the US Food and Drug 
Administration for the treatment of psoriasis but is also used off-label in the 
management of a variety of cutaneous diseases despite a lack of evidence-
based guidelines. 
They found that a moderate to strong recommendation was given for the use of 
topical vitamin D in combination with corticosteroids and phototherapy in vitiligo 
and as monotherapy for various ichthyoses, morphea, pityriasis alba, prurigo 
nodularis, and polymorphous light eruption. There is evidence showing that 
topical vitamin D is ineffective in the treatment of actinic keratosis, seborrheic 
keratosis, lichen planus, seborrheic dermatitis, alopecia areata, chemotherapy-
induced alopecia, and hypertrophic scars. 
They concluded from their study that topical vitamin D analogues have a 
significant role in the off-label treatment of dermatologic disease, but higher 
quality studies are still required. 
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Table 6.1: A listing of some drugs and their unlabeled indications: 
These listings were compiled from the USPDI8 and AHFS1 Drug Information 
 
Drug 
Unlabeled Use Relevant 
to Dermatology 
Approved Dermatologic 
Indications include 
Acyclovir 
Laser resurfacing, 
prophylaxis Chemical peel 
Wire-brush surgery 
Herpes genitalis, simplex 
& zoster prophylaxis 
Varicella – treatment 
Azelaic acid 
Melasma caused by 
hyperfunctioning 
melanocytes 
Acne vulgaris – mild to 
moderate 
Cimetidine 
Urticaria, acute in 
combination with an 
antihistamine 
Warts 
 
Clindamycin topical 
Eczema, infected 
Folliculitis caused by S. 
aureus. 
Impetigo, localized 
caused by S. aureus and 
beta-hemolytic 
streptococci, including S. 
pyogenes 
Clofazimine 
Has Orphan Drug status 
for: Leprosy, lepromatous 
(Hansen’s disease) 
Leprosy, dapsone 
resistant 
Other leprosy associated 
disease or inflammatory 
reactions. 
 
Corticosteroids Pemphigoid 
Sarcoid, localized 
Many inflammatory 
diseases are listed as 
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cutaneous 
Vitiligo 
corticosteroid responsive. 
Cyclosporine 
Atopic dermatitis 
Pyoderma 
gangranosum?? 
Transplant rejection –  
prophylaxis & treatment 
Psoriasis, chronic severe 
WHEN under the care of a 
qualified, suitably 
equipped specialist. 
Dapsone 
Actinomycotic mycetoma 
Cicatrial pemphigoid – 
desquamative gingival 
lesions 
Dermatosis, subcorneal 
pustular Granuloma 
annulare 
Lupus erythematosus, 
systemic – certain skin 
lesions 
Pemphigoid lesions with 
oral manifestations 
Polychondritis, relapsing 
Pyoderma gangrenosum 
Leprosy (Hansen’s 
disease) in combination 
with other agents 
Dermatitis herpetiformis 
Estrogen + 
cyproterone 
Acne in females 
Acne in females 
(approved in Canada) 
Estrogen + 
Progestin 
Hirsutism 
Acne in females also 
needing contraception 
Isotretinoin 
Acne, less severe than 
nodular 
Folliculitis Fordyce 
disease 
Severe rosacea including 
nodulocystic rosacea and 
Acne vulgaris – severe 
recalcitrant nodular 
35 
 
rosacea refractory to oral 
antibiotics 
Hidradenitis suppurativa 
Severe keratinization 
disorders such as 
ichthyosis & keratosis 
follicularis (Darier’s) 
Pityriasis rubra pilaris 
Methotrexate 
Dermatomyositis, 
systemic (polymyositis) 
Sarcoid 
Vasculitis 
Mycosis fungoides, 
advanced Numerous 
cancerous conditions 
Psoriasis, severe, 
resistant, recalcitrant, 
disabling 
Mupirocin 
Eczema, infected 
Folliculitis, localized 
caused by S. aureus 
Skin infections, minor 
Impetigo, localized 
caused by S. aureus and 
beta-hemolytic 
streptococci, including S. 
pyogenes 
Nitroglycerin 
Anal fissures ?? 
Hemorrhoids ??  
Sulfasalazine Psoriasis 
 
Thalidomide 
Has Orphan Drug 
classification for: 
Aphthous ulcers, in the 
terminally 
immunocompromised 
Graft v’s host disease 
Kaposi’s sarcoma 
Leprosy, reactional 
lepromatous Lupus 
erythematosus, cutaneous 
Erythema nodosum 
leprosum 
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Mycobacterial infection 
Tretinoin (retinoic 
acid, vitamin A acid) 
Actinic keratoses hands & 
arms 
Disorders of keratinization 
such as keratosis 
follicularis 
Icthyosis congenita & 
vulgaris Melasma 
Post-inflammatory facial 
hyperpigmentation 
Verruca plana. 
Acne vulgaris 
Hyperpigmentation, 
mottled, facial due to 
photoaging 
Skin roughness, facial, 
due to photoaging 
Wrinkling, fine facial, due 
to photoaging 
Trimethoprim 
Acne 
Pneumonia, 
Pneumocystis carinii (in 
the US) 
Pneumonia, 
Pneumocystis carinii in 
Canada but not in the US. 
 
 
6.1 Adverse drug reactions and off-label (unlicensed) medicines:  
Bellis et al. tested a hypothesis that off-label and unlicensed drug  (OLUL) 
status is a risk factor for adverse drug reactions (ADRs). Off-label and 
unlicensed (OLUL) prescribing has been prevalent in pediatric practice. They 
used data from a prospective cohort study of adverse drug reactions (ADRs) 
among pediatric inpatients.  A nested case–control study was conducted within 
a prospective cohort study. They concluded that off-label and unlicensed 
medicines are more likely to be implicated in an adverse drug reactions (ADR) 
than authorized medicines. The number of drugs administered is a risk factor 
for ADRs highlighting the need to use the lowest number of medicines, at the 
lowest dose for the shortest period, with continual vigilance by prescribers, in 
order to reduce the risk of ADRs. 
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Chapter 7.0 
Ethical Issues 
7.1 Full informed consent: 
Informed consent is the process by which the treating health care provider 
discloses appropriate information to a competent patient so that the patient may 
make a voluntary choice to accept or refuse treatment. (Appelbaum, 2007). It 
originates from the legal and ethical right the patient has to direct what happens 
to her body and from the ethical duty of the physician to involve the patient in 
her health care. 
The most important goal of informed consent is that the patient has an 
opportunity to be an informed participant in her health care decisions. It is 
generally accepted that informed consent includes a discussion of the following 
elements: 
- The nature of the decision/procedure 
- Reasonable alternatives to the proposed intervention 
- The relevant risks, benefits, and uncertainties related to each alternative 
- Assessment of patient understanding 
- The acceptance of the intervention by the patient 
In order for the patient's consent to be valid, she must be considered competent 
to make the decision at hand and her consent must be voluntary. It is easy for 
coercive situations to arise in medicine. Patients often feel powerless and 
vulnerable. To encourage voluntariness, the physician can make clear to the 
patient that he/she is participating in a decision-making process, not merely 
signing a form. With this understanding, the informed consent process should 
be seen as an invitation for the patient to participate in health care decisions. 
The physician is also generally obligated to provide a recommendation and 
share his reasoning process with the patient. Comprehension on the part of the 
patient is equally as important as the information provided. Consequently, the 
discussion should be carried on in layperson's terms and the patient's 
understanding should be assessed along the way. 
Basic or simple consent entails letting the patient know what a physician would 
like to do; giving basic information about the procedure and ensuring that the 
patient assents or consents to the intervention. Assent refers to a patient’s 
willing acceptance of treatment, intervention or clinical care. Basic consent is 
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appropriate, for example, when drawing blood in a patient who has given blood 
before. Sometimes consent to the procedure is implied (e.g. the patient came in 
to have blood drawn), but an explanation of the elements of the procedure 
remain necessary. Decisions that merit this sort of basic informed consent 
process require a low level of patient involvement because there is a high-level 
of community consensus that the treatment being offered is the only or best 
option and/or there is low risk involved in the management If a patient does not 
consent under the paradigm of basic consent, then a fuller informed consent 
discussion is warranted. 
 
7.1.1 Information for patients about the license for their medicines: 
General Medical Council (GMC) in UK determines what sorts of information 
must be given to patients (or their parents or carers) about the medicines that 
are proposed to prescribe to allow patients to make an informed decision. 
Some medicines are routinely used outside the terms of their license. In 
emergencies or where there is no realistic alternative treatment and such 
information is likely to cause distress, it may not be practical or necessary to 
draw attention to the license. In other cases, where prescribing unlicensed 
medicines is supported by authoritative clinical guidance, it may be sufficient to 
describe in general terms why the medicine is not licensed for the proposed use 
or patient population. Doctors must always answer questions from patients (or 
their parents or carers) about medicines fully and honestly. 
If doctors intend to prescribe unlicensed medicines where that is not routine or if 
there are suitably licensed alternatives available, doctors should explain this to 
the patient, and their reasons for doing so. 
Doctors should be careful about using medical devices for purposes for which 
they were not intended. 
 
7.1.2 Which sorts of interventions require informed consent? 
All health care interventions require some kind of consent by the patient, 
following a discussion of the procedure with a health care provider. Patients fill 
out a general consent form when they are admitted or receive treatment from a 
health care institution. Most medical institutions have policies that state which 
health interventions require a signed consent form. For example, surgery, 
anesthesia, and other invasive procedures are usually in this category. These 
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signed forms are the culmination of a dialogue required to foster the patient's 
informed participation in the clinical decision. 
For a broad range of decisions, explicit written consent is neither required nor 
needed, but some meaningful discussion is always needed. For instance, a 
man contemplating having a tumor marker S100 screen for malignant 
Melanoma (skin cancer) should know the relevant arguments for and against 
this screening test, discussed in lay terms. 
Does the use of off-label drugs require a higher standard of informed consent? 
 
7.1.3 How much information is considered "adequate"? 
How does the patient know when provided enough information about a 
proposed intervention? Most of the literature and law in this area suggest one of 
three approaches: 
Reasonable physician standard: what would a typical physician say about this 
intervention? This standard allows the physician to determine what information 
is appropriate to disclose. However, this standard is often inadequate, since 
most research shows that the typical physician tells the patient very little. This 
standard is also generally considered inconsistent with the goals of informed 
consent, as the focus is on the doctor rather than on what the patient needs to 
know. 
Reasonable patient standard: what would the average patient need to know in 
order to be an informed participant in the decision? This standard focuses on 
considering what a typical patient would need to know in order to understand 
the decision at hand. 
Subjective standard: what would this particular patient need to know and 
understand in order to make an informed decision? This standard is the most 
challenging to incorporate into practice since it requires tailoring information to 
each patient. 
Most states have legislation or legal cases that determine the required standard 
for informed consent. The best approach to the question of how much 
information is enough is one that meets both your professional obligation to 
provide the best care and respects the patient as a person, with the right to a 
voice in health care decisions. 
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7.1.4 Exceptions to fully informed consent: 
If the patient does not have decision-making capacity, such as a person with 
dementia, in which case a proxy, or surrogate decision-maker, must be found. 
A lack of decision-making capacity with inadequate time to find an appropriate 
proxy without harming the patient, such as a life-threatening emergency where 
the patient is not conscious 
When a competent patient designates a trusted loved one to make treatment 
decisions for him or her. In some cultures, family members make treatment 
decisions on behalf of their loved ones. Provided the patient consents to this 
arrangement and is assured that any questions about his/her medical care will 
be answered, the physician may seek consent from a family member instead of 
the patient. In some jurisdictions like Ireland nobody can consent on behalf of 
another person over the age of 18 (Appelbaum, 2007). 
In most cases, it is clear whether or not patients have the capacity to make their 
own decisions. Occasionally, it is not so clear. Patients are under an unusual 
amount of stress during illness and can experience anxiety, fear, and 
depression. The stress associated with illness should not necessarily preclude 
one from participating in one's own care. However, precautions should be taken 
to ensure the patient does have the capacity to make good decisions. There are 
several different standards of decision-making capabilities. Generally the 
physician should assess the patient's ability to: 
- Understand his or her situation, 
- Understand the risks associated with the decision at hand, and 
- Communicate a decision based on that understanding. 
When this is unclear, a psychiatric consultation can be helpful. Of course, just 
because a patient refuses a treatment does not in itself mean the patient is 
incompetent. Competent patients have the right to refuse treatment, even those 
treatments that may be life-saving. Treatment refusal may, however, be an 
indication that it is necessary to pause to discuss further the patient's beliefs 
and to understand about the decision. 
A patient’s decision-making capacity is variable as their medications or 
underlying disease processes ebb and flow. Doctors should do what they can to 
catch a patient in a lucid state - even lightening up on the medications if 
necessary and safe - in order to include her in the decision-making process. 
Delirious patients have waxing and waning abilities to understand information. 
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However, if a careful assessment is done and documented at each contact, and 
during lucid periods the patient consistently and persistently makes the same 
decision over time, this may constitute adequate decisional capacity for the 
question at hand. 
If the patient is determined to be incapacitated/incompetent to make health care 
decisions, a surrogate decision maker must speak for her. There is a specific 
hierarchy of appropriate decision makers defined by state law (DNR Orders 
during Anesthesia and Urgent Procedures, Washington State Medical 
Association). (What laws are you referring to) If no appropriate surrogate 
decision maker is available, the physicians are expected to act in the best 
interest of the patient until a surrogate is found or appointed. In rare 
circumstances, when no surrogate can be identified, a guardian ad litem may 
have to be appointed by the court. Confer with social work and risk 
management if doctors have trouble finding a legal surrogate for the patient. 
 
7.1.5 Informed consent for children: 
Children do not have the decision-making capacity to provide informed consent. 
Since consent, by definition, is given for an intervention for oneself, parents 
cannot provide informed consent on behalf of their children. Instead, they can 
provide informed permission for treatment. For older children and adolescents, 
assent should always be sought in addition to the authorization of legal 
surrogates. Adolescents and mature minors are legally and ethically authorized 
to provide informed consent if they are emancipated, and in many states, 
including Washington, they may provide consent for matters regarding sexual 
and reproductive health, mental health, and substance abuse. 
The primary responsibility of the physician is the well-being of the child. 
Therefore, if the parental decision places the child at risk of harm, then further 
action may be indicated. When there are differences in opinion between the 
parents and physicians that cannot be resolved ethics consultation may be 
pursued, and legal avenues may be pursued when all other means have failed. 
Children should be included in decision-making at a developmentally 
appropriate level and assent should be sought when possible.  
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7.1.6 Informed consent in emergency situations: 
The patient's consent should only be "presumed," rather than obtained, in 
emergency situations when the patient is unconscious or incompetent and no 
surrogate decision maker is available and the emergency interventions will 
prevent death or disability. In general, the patient's presence in the hospital 
ward, ICU or clinic does not represent implied consent to all treatment and 
procedures. The patient's wishes and values may be quite different from the 
values of the physician. While the principle of respect for person obligates you 
to do your best to include the patient in the health care decisions that affect 
patient’s life and body, the principle of beneficence may require physician to act 
on the patient's behalf when patient’s life is at stake. 
 
7.2 Patient Autonomy 
Once a drug has been approved by the FDA for one purpose, a physician can 
prescribe that drug for any purpose. The practice of prescribing a drug for a 
purpose other than that for which it is approved is known as “off-label” use. Off-
label use is legal and does not necessarily mean that the drug is being used 
inappropriately (Gazarian, M., et al., 2006). In fact, many physicians prescribe a 
drug off-label because they believe it is the best treatment for a particular 
condition even though it has not yet been formally tested for use in that status 
(Meadows, W.A. and Hollowell,  B.D., 2008). Off-label use becomes an ethical, 
not a legal, issue when the principle of informed consent is introduced. 
The concept of informed consent as it is currently understood arose in response 
to the many medical research abuses of the middle half of the twentieth century 
from the mid 1930s through the mid 1970s in Nazi Germany and the United 
States. Simply put, informed consent demands that patients give their consent 
to any treatment or research protocol that a clinician proposes. The “informed” 
part of the term forces us to ask: how much information must patients receive in 
order to be able to give “informed” consent? (Zain, M., 2012). 
Informed consent is a principle that is observed to ensure that patient autonomy 
is preserved, requiring that competent patients be made aware of and 
understand enough about the intended benefits and possible risks of proposed 
treatment to make an informed decision (Veatch, R.C., 1997). This consent can 
be implied by the patient’s lack of protest, and, in the case of many routine 
medical interventions. The FDA requires explicit written consent for drugs being 
used experimentally or as a part of research, but no explicit consent is required 
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for any off-label drug use if it can be argued that, like any other treatment, the 
drug is being used in the patient’s best interests (Committee on Drugs, 2002). 
On the other hand, some people argue that off-label use is not be requiring an 
informed consent. One may wonder why, even though the ethical and legal 
principles of informed consent and shared decision-making are not being 
upheld, off-label use has become so prevalent in the daily practice of medicine. 
The lack of scientific support for most drug use of this type should serve to 
heighten these concerns. Some contend, however, that there are logical 
reasons not to inform patients of a drug’s off-label status and instances in which 
off-label use is actually beneficial (Zain, M., 2012). 
The most commonly used defense of off-label drug use is that acquiring FDA 
approval for all uses is not economically feasible. This is especially true in 
pediatric care, in which three-fourths of prescription drugs are used off-label 
(Gazarian, M., et al., 2006). It is not cost-effective for pharmaceutical 
companies to get drugs reapproved for children or for other uses (Committee on 
Drugs, 2002). Once a drug is determined to be safe and efficient for one use, 
the pharmaceutical industry relies on the off-label market to expand its sales 
potential. 
 
7.3 Relationship between doctors and drugs companies: 
A majority of physicians don't consider it unethical to accept such gifts as 
receipt of pens, pen-stand, pads, calendars, drug samples, company funded 
lunch or dinner etc at which company's products are favorably mentioned. 
However, acceptance of expensive gifts of recreational value rather than 
professional activities is unethical according to them. Also, they concur not to 
support medical products of drug companies whose medical representatives 
furnish biased or self-serving information regarding their products. Even among 
those doctors who claim that they only prescribe medicines that are most 
beneficial to their patients irrespective of the fact that they are constantly visited 
and pressurized by pharmaceutical companies to prescribe their brands only - a 
substantial body of evidence suggests otherwise. Because when a gift is given, 
is imposes on a doctor a scene of indebtedness. As an upright man instructed 
in the art of healing, he may feel inclined to reciprocate resulting in shoddy 
prescriptions. 
As a consequence of the relationship between doctors and drug companies, the 
credibility of the medical profession in the eyes of the patients and the public is 
ever on the decline. If a patient gets to know that the doctor is prescribing drug 
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or medical advice on the basis of commercial influence he may lose trust and 
confidence in the doctor (which are the precursors to any successful treatment). 
In such a scenario, patients are more likely than doctors to believe that gifts 
may influence prescribing behavior that is morally inappropriate according to 
them. 
Medicine is a noble profession. The primary aim of the medical profession is to 
render service to humanity. Financial gain is a subordinate consideration. 
However, it has been observed globally that health care practitioners in 
conjunction with pharmaceutical companies are prescribing and thereby 
promoting unnecessary drugs just for the sake of monetary gains. This article 
reviews the salient aspects of the relationship between doctors and drugs 
companies and its future consequences. 
The interaction between doctors and medical representatives is almost as old 
as the medical profession itself. The basic role of a medical representative is to 
apprise the doctor about his company's products including the drugs. There is 
nothing wrong in that as long as the ultimate beneficiary of this information is 
the patient. After all, continued professional development is an essential 
component of a good health care system. Even the Medical Council of India 
expects that every registered medical practitioner should try to upgrade his 
knowledge and skill for the betterment of his patients. 
Unfortunately, there is often a conflict between the interests of the patient and 
those of the doctors as far as the drug promotion is concerned. WHO defines 
drugs promotion as all informational and persuasive activities by manufacturers, 
distributors to induce /influence the sale and use of medicinal drugs. Drug 
promotion has an important bearing on the rational use of a drug; on drug -price 
control mechanism; on equity of drug distribution - all making it a central public 
health issue. Often, drug promotion strategies adopted by various 
pharmaceutical companies are too attractive to be resisted by a doctor. This, in 
turn, places the interest of the doctors ahead that of the patients. Doctors, who 
are frequently in contact with medical representatives, are more likely to 
prescribe newer and expensive drugs of their favorite pharmaceutical 
companies to achieve their selfish end i.e. to receive more and more financial 
gain from the companies as cutbacks. In our country, the doctors are held in 
high esteem by the gullible patients. They are considered second to 'Gods' by 
most patients. Therefore, doctors may prescribe expensive drugs of their 
favorite pharmaceutical companies with scant regard for the expense borne by 
the poor patients. Interaction between drug companies and doctors are 
pervasive. Relationships of doctors with drug companies begin when they are 
just medical students attending the various clinical OPD's and wards, continue 
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during internship and residency training, and persist throughout their 
professional careers. 
 
7.3.1 The Nature and Effect of the Relationships: 
The drug companies interact with doctors in order to promote their medical 
products. They reach out to almost all concerned doctors to attain their goals. 
The doctors are compensated adequately in the form of gifts and other 
incentives to drug companies. Consequentially, both the parties are benefited 
from this interaction with potential consequences for patients. Few doctors may 
be morally so stout that they continue to prescribe those medicines that appear 
to be most beneficial as well as economical to their patients despite being in 
contact with so many drug companies. The aggressive marketing strategies by 
the companies just act as tools of information for them. However, the 
prescribing behavior of a vast majority of the medical community is palpably 
influenced by pharmaceutical companies. Many physicians believe that their 
interactions with drug companies have educational value for themselves and 
also provide benefits for patients, because physicians are kept informed about 
available therapeutic agents and the poor patients can be given free drug 
samples provided by different companies. Some physicians contend that they 
themselves are invulnerable to any bias as a result of interaction with drug 
companies. 
There is a growing consensus among doctors that prescribing more expensive 
brands of reputed companies of which the quality is assured is far better than 
prescribing cheaper brands of unknown quality. This may be one of the reasons 
behind such shoddy prescriptions. However, this cannot be generalized. It is an 
open secret that the professional associations depend solely on pharmaceutical 
companies to sponsor their medical programs, CME's, Conferences, Annual 
Meeting, Workshops, “etc”. Many junior, as well as senior physicians, seek 
sponsorships or financial aids from these companies to attend national as well 
as International Conferences. Even pleasure- trips within the country and 
abroad for a few heavyweight doctors and their immediate family members are 
arranged and funded by some pharmaceutical companies. The doctors, in turn, 
tend to reciprocate by prescribing medical products of these firms in blatant 
disregard to patient's welfare. In one study, it was found that there are many 
different ways by which drug companies relate directly or indirectly to doctors. 
These range from the seemingly trivial (e.g., the ubiquitous dispensing of gifts 
such as pens and writing pads with drug names inscribed) to the much more 
fascinating gifts(e.g., the ghost writing of articles for teaching faculty, the 
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payment of large sums in cash to prominent physicians who extol the virtues of 
company products and the support of lavish trips and entertainment for doctors 
who commonly prescribe company products). 
It is being realized more now than ever before that the interaction between 
doctors and drug companies should be contained within acceptable boundaries. 
It would be impracticable to ask the medical professionals to distance 
themselves from pharmaceutical companies. The real challenge for the medical 
profession, drug companies and the government is to formulate mutually 
acceptable guidelines to avoid certain egregiously unethical medical practice. 
The ultimate arbiter of this malpractice is, of course the medical profession 
itself. It is for them to decide whether or not to accept the proffered information 
and gifts from drug companies. For that, medical students should be exposed to 
the marketing strategies of pharmaceutical companies and the methods to 
counter them. During MBBS course, the students should be instructed not to 
depend on drug companies for their professional advancement. As the doctors 
posted in rural or remote areas are supposedly not aware of the latest trends in 
medical practice, they depend on the drug companies for product information. 
This problem can be obviated if more and more CME's are conducted in those 
areas by registered medical association so that they can keep pace with 
emerging medical technology. Professional associations should also strive hard 
to generate funds so that they can conduct their scientific programs 
independently. Mushrooming of drug companies is also responsible for this 
unethical medical practice. Since, one pharmaceutical company in order to 
surpass another company brings out the same drug at much cheaper price, 
compromising the quality of the drug. If the retail price and the quality of the 
drug are regulated and standardized by the Government. The unethical practice 
of drug companies can be put in check. However, before that we have to 
understand the dynamics of Indian drug bazaar that involves not only the 
doctors and the drug companies but also the go-in-betweens like a chemist and 
medical representatives, “etc”. However then, all said and done, the only 
pragmatic approach to dealing with this unethical practice is for doctors not to 
accept anything of financial value from drug companies. Till date apart from the 
American Medical Association and others, the Indian Medical Association has 
also expressed its concern over it and made an appeal to the medical 
community not to accept expensive gifts from pharmaceutical companies. 
 
In summary, Ethical issues surrounding the threat to patient autonomy, 
informed consent and the impact on the physician-patient relationship and 
physician-drug company relationship are some of the main ethical concerns to 
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be raised when using off-label medications in dermatology. Although eliminating 
off-label use is unfeasible, preventing them from being used deceptively is 
imperative based on the numerous ethical issues discussed. 
 
Chapter 8.0 
Legal Issue: 
8.1 Regulations of off-label use in various countries 
8.1.1 United States 
In the United States, no law prohibits a physician or other healthcare 
practitioner from prescribing an approved medication for other uses than their 
specific FDA-approved indications.[citation needed] Pharmaceutical companies 
are not allowed to promote a drug for any other purpose without formal FDA 
approval. Marketing information for the drug will list one or more indications, 
that is, illnesses or medical conditions for which the drug has been shown to be 
both safe and efficient. 
However, once a drug has been approved for sale for one purpose, physicians 
are free to prescribe it for any other purpose that in their professional judgment 
is both safe and effective, and are not limited to official, FDA-approved 
indications. This off-label prescribing is most commonly done with older, generic 
medications that have found new uses but have not had the formal and often 
costly applications and studies required by the FDA to formally approve the 
drug for these new indications. However, there is often extensive medical 
literature to support the off-label use. 
A leading example of how regulatory agencies approach off-label use is 
provided by the United States Food and Drug Administration (FDA)'s Center for 
Drug Evaluation and Research, which reviews a company's New Drug 
Application (NDA) for clinical trial data to see if the results support the drug for a 
specific use or indication. If satisfied that the drug is safe and effective, the 
drug's manufacturer and the FDA agree on specific language describing 
dosage, route of administration, and other information to be included on the 
drug's label. More detail is included in the drug's package insert. 
The FDA approves a drug for prescription use, and continues to regulate the 
pharmaceutical industry's promotional practices for that drug through the work 
of the Office of Prescription Drug Promotion (OPDP, formerly the Division of 
Drug Marketing, Advertisement and Communication (DDMAC). The FDA does 
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not have the legal authority to regulate the practice of the medicine, and the 
physician may prescribe a drug off-label. Contrary to popular notion, it is legal in 
the United States and in many other countries to use drugs off-label, including 
controlled substances such as opiates. Actiq, for example, is commonly 
prescribed off-label even though it is a Schedule II controlled substance. While 
it would be legal for a physician to decide independently to prescribe a drug 
such as Actiq off-label, it is illegal for the company to promote off-label uses to 
prescribers. In fact, Cephalon, the maker of Actiq, was fined for illegal 
promotion of the drug in September 2008. Under the Food, Drug, and Cosmetic 
Act (FDCA) at U.S.C. 21 §§301-97, manufacturers are prohibited from directly 
marketing a drug for a use other than the FDA-approved indication. However, in 
December of 2012, the United States Second Circuit Court found that 
promotion of off-label uses by a company sales representative was considered 
to be protected speech per the First Amendment. In addition, The Food and 
Drug Administration Modernization Act of 1997 created an exception to the 
prohibition of off-label marketing, allowing manufacturers to provide medical 
practitioners with publications on off-label uses of a drug, in response to an 
unsolicited request. In 2004, the federal government and whistleblower David 
Franklin reached a $430 million settlement in Franklin v. Parke-Davis to resolve 
claims that Warner-Lambert engaged in off-label promotion of Neurontin in 
violation of the FDCA and the False Claims Act. At the time, the settlement was 
one of the largest recoveries against a pharmaceutical company in U.S. history, 
and the first off-label promotion settlement in U.S. history. 
 
8.1.2 United Kingdom 
Physicians in the United Kingdom can prescribe medications off-label. 
According to the British General Medical Council, off-label prescriptions must 
better serve patient needs than alternatives and must be supported by evidence 
or experience to demonstrate safety and efficacy. 
 
8.1.2.1 Prescribing guidance: the guidelines on prescribing medicines by 
GMC 
General Medical Council (GMC) in the UK (2013) puts guidelines to regulate 
prescribing medications: 
1. In Good medical practice: 
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Doctors must keep up to date with, and follow, the law, our guidance and other 
regulations relevant to their work. Doctors must recognize and work within the 
limits of their competence. In providing clinical care, doctors must: 
a. Prescribe drugs or treatment, including repeat prescriptions, only when 
doctors have adequate knowledge of the patient’s health and are satisfied that 
the drugs or treatment serve the patient’s needs. 
b. Provide effective treatments based on the best available evidence 
c. Check the care or treatment provided for each patient is compatible with any 
other treatments the patient is receiving, including (where possible) self-
prescribed over-the-counter medications. 
Doctors must make a good use of the resources available to the patients. 
Documents that doctors make (including clinical records) to formally record their 
work must be clear, accurate and legible. Doctors should make records at the 
same time as the events are recording or as soon as possible afterwards. 
Clinical records should include: 
a. Relevant clinical findings. 
b. The decisions made, actions agreed and who is making the decisions and 
agreeing the actions. 
c. The information given to patients. 
d. Any drugs prescribed or other investigation or treatment requested. 
e. Who is making the record and when? 
2. This guidance provides more detailed advice on how to comply with these 
principles when prescribing and managing medicines and medical devices, 
including appliances. 
3. Doctors are responsible for the prescriptions they sign and their decisions 
and actions when they supply and administer drugs and devices or authorize or 
instruct others to do so. Doctors must be prepared to explain and justify their 
decisions and actions when prescribing, administering and managing 
medicines. 
4. 'Prescribing' is used to describe many related activities, including prescribing 
medicines, devices and dressings on the NHS and advising patients on the 
purchase of over the counter medicines and other remedies. It may also be 
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used to describe written information provided for patients (information 
prescriptions) or advice given. While some of this guidance is particularly 
relevant to prescription only medicines, doctors should follow it in relation to the 
other activities undertook, so far as it is relevant and applicable. This guidance 
applies to medical devices as well as to medicines. 
5. Serious or persistent failure to follow this guidance will put doctors 
registration at risk. 
 
8.1.2.2 General Medical Council (GMC) regulations for prescribing 
unlicensed medicines 
Healthcare professionals should usually prescribe licensed medicines in 
accordance with the terms of their license. However, healthcare professionals 
may prescribe unlicensed medicines, on the basis of an assessment of the 
individual patient, that it is necessary to do so to meet the particular needs of 
the patient. 
Prescribing unlicensed medicines may be required where: 
a. No suitably licensed medicine that will meet the patient’s need. Examples 
include (but are not limited to) where: 
i) There is no licensed medicine applicable to the particular patient. For 
example, if the patient is a child and a medicine licensed only for adult patients 
would meet the needs of the child; or 
ii) A medicine licensed to treat a condition or symptom in children would 
nonetheless not meet the specifically assessed needs of the particular child 
patient, but a medicine licensed for the same condition or symptom in adults 
would do so; or 
iii) The dosage specified for a licensed medicine would not meet the patient’s 
need; or 
iv) The patient needs a medicine in a formulation that is not specified in an 
applicable license, or 
b. A suitably licensed medicine that would meet the patient’s need is not 
available. This may arise where, for example, there is a temporary shortage in 
supply; or 
c. The prescribing forms are part of a properly approved research project. 
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When prescribing an unlicensed medicine, doctors must: 
a. Be satisfied that there is sufficient evidence or experience of using the 
medicine to demonstrate its safety and efficacy 
b. Take responsibility for prescribing the medicine and for overseeing the 
patient’s care, monitoring and any follow-up treatment or ensure that 
arrangements are made for another suitable doctor to do so. 
c. Make a clear, accurate and legible record of all medicines prescribed where 
not following a common practice and reasons for prescribing an unlicensed 
medicine. 
 
8.2 Do Physicians Expose Themselves to Legal Vulnerability for Including 
OLDUs in Their Clinical Practices, Particularly if the Patient Experiences 
an Adverse Reaction Related to an OLDU? 
Physicians have been involved in legal claims due to an adverse reaction 
related to a medication prescribed for an off-label use. The legal theories used 
in these lawsuits include the unregulated use of a research drug, failure to 
provide adequate informed consent for an OLDU and medical negligence. In 
developing legal precedents for off-label therapies, the courts have typically 
treated medicines and devices as coequals. As such, many of the tribunals' 
views on OLDU have evolved from decisions regarding off-label uses of 
medical devices. 
 
8.3 Research vs. Practice 
The FDA makes it clear that it does not regulate the practice of medicine and 
that the Federal Food, Drug, and Cosmetic Act of 1938 will not play a role in 
creating physician liability for OLDU. However, the FDA requires stringent 
review before drugs and medical devices be involved in research to ensure that 
steps are taken to protect properly human study participants. When not 
classified as tools involved in research, medications can be prescribed and 
medical devices can be used in an off-label manner without FDA regulatory 
oversight. Regarding this point, during its evaluation of possible harm arising 
from placement of an orthopedic spine medical device, an Ohio appellate court 
stated that “the off-label use of a medical device is merely a matter of medical 
judgment and, as such, subjects a physician to professional liability for 
exercising professional medical judgment, but off-label use of a medical device 
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is not barred by the U.S. Food and Drug Administration”. By way of legal 
precedent and similar FDA regulatory processes, the same standard would 
apply to OLDU. 
Drawing a clear line of demarcation between a drug's use in research vs. 
practice can often be difficult. Prescribing a drug in a new and yet untested 
manner does not alone brand it as an interest of research. The National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research has attempted to define whether a drug's use might be classified as a 
practice or research tool, and their definitions follow. The goal of medical 
practice is to “provide diagnosis, preventative treatment or therapy”. Research, 
on the other hand, is “designed to test a hypothesis, permit conclusions to be 
drawn, and thereby to develop or contribute to generalizable knowledge”. When 
not deemed research, legal claims brought solely on the basis of failure to gain 
adequate FDA approval before prescribing an off-label drug will likely be struck 
down. However, physicians may not be sheltered from other forms of liability 
theories. 
 
8.4 Medical Malpractice: 
8.4.1 Medical Malpractice: Informed Consent 
No court decision to date has mandated that a physician must disclose, through 
an informed consent process, the off-label use of a drug. Two arguments are 
often voiced by those who oppose any routine requirement for disclosure: (1) 
disclosure may unduly frighten patients and (2) the extensive burden placed on 
physicians to constantly review and communicate medication risk and benefit 
information may divert attention away from other more important patient care 
issues. 
Perhaps the most cited modern legal case involving the medical informed 
consent process is Canterbury v Spence. The Canterbury Court held that “the 
test for determining whether a particular peril must be divulged is its materiality 
to the patient's decision”. A material risk is one in which “a reasonable person, 
in what the physician knows or should know to be the patient's position, would 
be likely to attach significance to the risk or cluster of risks in deciding whether 
or not to forego the proposed therapy”. 
Many courts have not considered OLDU to be an independent material issue 
requiring disclosure during the consent process. A 1996 Ohio court held that 
off-label use of medical devices was a “matter of medical judgment”. According 
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to the court, physicians may be subject to professional liability for medical 
negligence involving OLDU but will not be held liable for nondisclosure. 
The results of a 2006 nationwide poll on the public's view of OLDU may 
precipitate concerns for future court challenges not fully appreciated by 
previous legal opinion. Half of the poll's respondents falsely believed that a drug 
could be prescribed only for its primary FDA-approved use. An almost similar 
percentage felt that physicians should be prohibited from prescribing drugs for 
off-label use. Nearly two-thirds of those responding felt that except for use in 
clinical trials, OLDU should be completely banned. This is a remarkable 
aggregate response given that a considerable fraction of those responding 
negatively to OLDU had likely benefited from the practice at some point in their 
lives (although they were probably unaware). 
Although many courts do not require physicians to disclose OLDU, patients may 
have a different belief and concern regarding their use. Whether these matters 
will develop into a greater expectation for adequate disclosure remains 
unknown. Some physicians have suggested that providing patients with 
information about OLDU may afford greater protection from future liability suits. 
 
8.4.2 Medical Malpractice: Negligence 
Medical malpractice is a broad term that includes the action of negligence. In 
fact, 4 elements of tort law dealing with negligence must be proved before 
liability can be found to exist: (1) the prescribing physician must have a duty to 
the patient, (2) that duty must be breached, (3) there must be some injury 
requiring compensation, and (4) there must be a causal link between the breech 
and that injury. 
A physician's duty of care is defined as the same degree of care provided by 
other physicians practicing under similar circumstances. Use of off-label 
medication alone does not result in liability under negligence standards. When a 
patient believes that he or she was harmed by an off-label use of a drug, it must 
be established that the prescribing physician deviated from the standard of 
practice.38 Because the FDA prohibits manufacturers from sponsoring 
physician education for off-label use of their medications, physicians may find it 
difficult to establish how others in their field are using medications outside their 
FDA-approved uses. As peer-reviewed published evidence focusing on a drug's 
off-label use grows over time, new standards of practice involving the off-label 
use of a drug begin to develop. 
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To help determine whether the standards of practice are being met when 
prescribing medications for OLDU, physicians should first ask themselves 
several questions: (1) Does the native drug have FDA approval? (2) Has the 
off-label use been subjected to substantial peer review? (3) Is the off-label use 
medically necessary for treatment? (4) Is the use of the medication non-
experimental? To mitigate the risk of liability, physicians should always 
prescribe off-label drugs in “good faith, in the best interest of the patient, and 
without fraudulent intent”. This 3-pronged approach to prescribing medications 
will also ensure that the tenets of the FDA‘s requirement are met; specifically, 
physicians prescribing medications for off-label use should “be well informed 
about the product, to base its use on firm scientific rationale and on sound 
medical evidence, and to maintain records of the product's use and effects”. 
 
8.5 Practical implications: 
FDA-approved drugs for off-label indications, and unlabeled drug uses, have 
played a significant role in the way in which we treat skin disease. A good 
example is the use of thalidomide to treat the cutaneous manifestations of 
erythema nodosum leprosum, first reported in 1965, recommended by the WHO 
in 1988 and finally approved by the FDA in September 1997 (Thalidomide. Skin 
Therapy Letter 1997). 
If the unlabeled use of a drug is for treatment rather than research, this 
constitutes innovative therapy and appears to be within the physician’s ethical 
and legal prerogative supported by FDA regulations, common law, and ethical 
cannons (Torres, A., 1994). Although the off-label use of a drug is not 
necessarily an improper use of the drug, there is no regulatory body approved 
information on risk/benefit available. In this situation, the prescriber has to 
utilize consultation with colleagues, plus information gained from the package 
insert and a review of the medical literature (Shapiro, S.A., 1979). The ethical 
and legal implications of this situation are not always clear. Although no specific 
informed consent appears to be required, unlabeled drug use best serves the 
patient and protects the physician from liability when it is accompanied by 
informed consent that adequately informs the patient of the innovative nature of 
the therapy together with the greater uncertainty of risk (Torres, A., 1994). As 
recent well-known cases have shown, extra care must be taken to ensure that 
the physician and the patient are both well-informed of the risks and benefits, so 
their collaboration can result in the best possible clinical outcome (Reardon, F., 
1997). 
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Ultimately, regardless of the legality of unlabeled drug use, if an approved drug 
is used for unlabeled purposes, a physician should carefully weigh the 
risk/benefit of the utilization of the drug before, during and after treatment 
(Torres, A., 1994). 
 
8.6 The Reasons for FDA policies on off-label use: 
The current situation permits a company to promote the labeled use of a new 
drug. Permitting sponsors to promote off-label uses would diminish or eliminate 
the company’s incentive to carry out clinical trials and obtain definitive data. 
Such activity could result in harm to the patient, or fail to show that the drug is 
effective. If there is a deliberate attempt to diminish the use of evidence-based 
medicine in arriving at safety and efficacy decisions concerning a drug, the 
regulatory process will be eroded (Woodcock, J., 1997). Pharmaceutical 
companies could get approval for a drug for some narrow use and then heavily 
promote it for much broader uses that had not been adequately tested (The 
dangers of off-label drug promotion, Public Citizen Internet URL).  What if 
preliminary findings are not subsequently borne out by further study or are 
refuted by other studies?  
Decisions on efficacy should be based on significant results, obtained from well 
designed and administered clinical trials, published in peer-reviewed journals. 
Peer judgment and review are essential for balanced results. 
 
In summary, legal issues including unclear regulations in many countries, FDA 
policies, medical malpractice and reasonable patient standards add increasing 
complexity. Although eliminating off-label use is unfeasible, preventing them 
from being used deceptively is imperative based on the numerous legal issues 
discussed. 
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Chapter 9.0 
Recommendations: 
9.1 Recommendations for patients: 
■ When your doctor prescribes a drug -any drug – (includes: tablet, capsule, 
syrup, ointment, cream, gel, solution, lotion and shampoo),  ask if it’s an 
approved use or an “off-label” use. 
■ If your doctor does not know, that’s not reassuring. Ask the pharmacist the 
same question. 
■ If the drug is being prescribed off-label, ask what the drug has been approved 
for. 
■ If you get an off-label prescription, ask your doctor whether the scientific 
evidence really supports this use. 
■ Go online and research the drug. Try to find the “label” — that is, the official 
printed information that specifies what the drug is approved to treat. The best 
place to start is the FDA’s Web site search engine for drugs at 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. 
■ Check other trusted Internet sites. If reassured, good. If further concerns are 
raised, talk with your doctor again. 
■ A drug that is often used off-label is not necessarily a signal that the off-label 
use is useful and beneficial. 
■ Don’t accept from a doctor or pharmacist the statement, “everyone prescribes 
this off-label. It is OK. What is his or her specific reason for prescribing the 
drug? 
 
9.2 Recommendations for prescribers: 
■ Be satisfied that an alternative, licensed medicine would not meet the 
patient’s needs before prescribing an unlicensed medicine. 
■ Be satisfied that such use would better serve the patient’s needs than an 
appropriately licensed alternative before prescribing a medicine off-label. 
■ Before prescribing an unlicensed medicine or using a medicine off-label, 
prescribers should: 
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■ Be satisfied that there are a sufficient evidence base and/or experience of 
using the medicine to show its safety and efficacy. 
■ Take responsibility for prescribing the medicine and for overseeing the 
patient’s care, including monitoring and follow-up. 
■ Record the medicine prescribed where common practice is not being followed 
and the reasons for prescribing this medicine. Prescribers may wish to record 
that they have discussed the issue with the patient. 
 
9.3 Best practice for communication includes: 
Physicians give patients, or those authorizing treatment on their behalf, 
sufficient information about the proposed treatment, including known severe or 
common adverse reactions, to enable them to make an informed decision. 
Where current practice supports the use of a medicine outside the terms of its 
license, it may not be necessary to draw attention to the license when seeking 
consent. However, it is good practice to give as much information as patients 
require or which they may see as relevant. 
Explain the reasons for prescribing a medicine off-label or prescribing an 
unlicensed medicine where there is little evidence to support its use, or where 
the use of a medicine is innovative. 
Healthcare professionals have a responsibility to help monitor the safety of 
druds in clinical use through submission of suspected adverse drug reactions. 
Such reporting is equally important for unlicensed medicines or those used off-
label as for those that are licensed. 
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Chapter 10 
Conclusion: 
Despite the controversy over the therapeutic use of off-label prescribing 
medications without a full disclosure,  off-label medications seem to be 
commonly prescribed in clinical practice in dermatology and venereology fields. 
However, prescribing off-label medications to patients who expect to receive an 
effective treatment will likely lead to foreseeable ethical and legal difficulties. 
Ethical issues surrounding the threat to patient autonomy, informed consent 
and the impact on the physician-patient relationship and physician-drug 
company relationship are some of the main ethical concerns to be raised. In 
addition, legal issues including unclear regulations in many countries, FDA 
policies and reasonable patient standards add increasing complexity. Although 
eliminating off-label use is unfeasible, preventing them from being used 
deceptively is imperative based on the numerous ethical and legal issues 
discussed.  
Off-label use in children is common and differs between countries, inpatient and 
outpatient settings and age. Allergy medicines are on the top of the most 
prescribed off-label drugs in children in dermatology, nevertheless this has not 
been accompanied by new research on their safety and efficacy in children, 
especially with those drugs already in market. In this narrative review, it was 
recognized that a high percentage of drugs prescription in an allergist daily 
clinical practice are off-label. It is fundamental to increase awareness of this 
reality, as it is the responsibility of the clinician to balance risk-benefits of the 
prescription. Parents/guardians should be informed and involved in the decision 
in order to prevent misunderstandings, increase compliance and awareness to 
adverse effects in the pursuance of a good clinical outcome. There is a need for 
new studies with a better design to access long-term safety and efficacy of 
respiratory and allergy to market drugs in children, primarily in those under two 
years of age. New ways should be found by the competent authorities to 
promote more research accordingly to the patients’ needs. 
The issue of going off-label involves both the doctor and the patient. The patient 
needs to understand that the doctor is prescribing the drug for a non-approved, 
or off-label use, and he or she needs to understand the risks and consequences 
of that particular regimen as well as the benefits. 
In addition, informed consent must be obtained. My suggestion is to get written 
consent to document the fact that an informed consent discussion occurred and 
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that the patient is aware of the risks and benefits of this proposed off-label and 
unlicensed drug use. 
Certainly, I would be extremely reluctant to suggest that medications be used 
off-label for minors because the potential consequences are significant if 
something goes wrong. 
I urge any doctor who wishes to prescribe for an off-label use to be extremely 
confident that the drug is appropriate for that use and be willing to face the 
consequences if his or her judgment is in error. I urge dermatologists to take a 
very cautious approach to using any medication off label. It’s highly unlikely that 
I would do it myself. It would have to be an extremely rare case where no other 
approved therapy would work. 
One of the primary reasons for my reluctance is the liability issue. If the patient 
has an adverse reaction to this particular medication, even if a dermatologist 
obtains informed consent, the dermatologist may be found liable. Additionally, 
the action could be viewed as reckless or wanton. That could lead to 
significantly greater financial responsibility on the part of the prescribing doctor.  
I cannot, and will not, recommend that dermatologists prescribe medications 
outside of their indications. If you do go off-label, another issue is the possibility 
that your malpractice insurance may not protect you. It protects you from acts or 
omissions in the practice of your profession that may not include going off-label. 
A management guideline for off-label drug use is urgently needed, with which 
we can guide medical institutions to establish the management regulations of 
off-label drug use. Clinical research should be promoted actively, and 
pharmaceutical enterprises should be encouraged to provide completely drug 
information. Academic organizations should be invited to join in for best 
professional drug use. 
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